Company intelligence / Profile preview

Step-In Pharma

Saint-Genis-Pouilly, Auvergne-Rhône-Alpes, Francestep-inpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Step Pharma is developing dencatistat (STP938), a first-in-class, highly selective oral inhibitor of CTPS1. The drug has entered clinical development for lymphoma, with additional studies planned or ongoing in solid tumours and essential thrombocythaemia. Early data supports its potential as a targeted therapy with the possibility of accelerated approval from single-arm Phase II studies.

Therapeutic areas: OncologyHematology
Modalities: Small molecule (oral drugs)
Industry: Biotech

Partnerships

Sygnature Discovery [founding collaboration]Kurma Partners [founding VC]

Beyond the preview

Go deeper on Step-In Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Step-In Pharma.

Explore the full profile